Keywords
wild poliovirus
poliomyelitis
poliovirus vaccine
How to Cite
Abstract
Poliomyelitis is an endemic disease in Afghanistan and Pakistan in despite of the efforts to eradicate it, and it represents a threat to other countries mainly due to the international trips. The World Health Organization (WHO) aims at eradicating the polio disease worldwide. An essential requirement for eradicating the poliomyelitis is the elimination of the wild poliovirus strain, which is employed in the gold standard test. As a support for the eradication of wild poliovirus, the present study aimed at modifying the gold standard test by using poliovirus derived from the oral attenuated vaccine. Sixty-three sera samples were tested by neutralization assay using vaccine antigens. The degree of agreement of the serotype 1 (k=0.74) was considered substantial, while the serotype 2 (k=1.00) and 3 (k= 0.95) showed almost perfect agreement. The sensitivity of serotypes 1, 2 and 3 was 94.83%, 100.00% and 100.00%, respectively. In conclusion, the assay with the vaccine antigens can be used as a safe application, especially for large-scale surveillance studies.
References
1. Racaniello VR. The poliovirus receptor: a hook, or an unzipper? Structure. 1996;4(7):769-73. https:// doi.org/10.1016/S0969-2126(96)00083-4
2. Hogle JM, Chow M, Filman DJ. The structure of poliovirus. Sci Am. 1987;256(3):42-9. https://doi. org/10.1038/scientificamerican0387-42
3. Salk JE. Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc. 1953;151(13):1081-98.
4. Sabin AB. Properties and behavior of orally administered attenuated poliovirus vaccine. J Am Med Assoc. 1957;164(11):1216-23. https://doi.org/10.1001/jama.1957.62980110008008
5. Friedrich F. Rare adverse events associated with oral poliovirus vaccine in Brazil. Braz J Med Biol Res. 1997;30(6):695-703. http://dx.doi.org/10.1590/S0100-879X1997000600001
6. Nkowane BM, Wassilak SG, OrensteinWA, Bart KJ, Schonberger LB, Hinman AR et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987;257(10):1335–40. http://dx.doi.org/10.1001/ jama.1987.03390100073029
7. Costa-Carvalho BT, Sullivan KE, Fontes PM, Aimé-Nobre F, Gonzales IGS, Lima ES et al. Low rates of poliovirus antibodies in primary immunodeficiency patients on regular intravenous immunoglobulin treatment. J Clin Immunol. 2018;38(5):628-34. https://doi.org/10.1007/ s10875-018-0531-x
8. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol. 1998;36(10):2893–9.
9. Dias-Tosta E, Kückelhaus CS. Neurological morbidity in vaccine-associated paralytic poliomyelitis in Brazil from 1989 up to 1995. Arq Neuropsiquiatr. 2004;62(2):414-20. http://dx.doi. org/10.1590/S0004-282X2004000300008
10. Ministério da Saúde - Brasil. Informe Técnico da introdução da vacina inativada poliomielite. [acesso 2018 Jun 22]. Disponível em: http:// www.sgc.goias.gov.br/upload/arquivos/2012-08/ infor me-te cnico-int ro ducao-da-vacina- inativada-poliomielite-vip-2012.pdf
11. Iniciativa de Erradicação Global da Pólio. Pólio hoje. [acesso 2018 Jun 05]. Disponível em: http:// polioeradication.org/polio-today/polio-now/ this-week/
12. Word Health Organization - WHO. Polio Global Eradication Iniciative-Polio Eradication & Endgame Strategic Plan 2013-2018.[acesso 2018 Jun 13]. Disponível em: http://polioeradication. org/wp-content/uploads/2016/07/PEESP_EN_ A4.pdf
13. World Health Organization – WHO. Weekly epidemiological record. 2016;91(19):249-256. [acesso 2018 Mai 28]. Disponível em: http://www. who.int/wer/2016/wer9119/en/
14. Word Health Organization - WHO. Global action plan for laboratory containment of wild polioviruses. 2.ed. Geneva:WHO;2003. [acesso 2018 Mai 29]. Disponível em: h t t p://a p ps.w h o .in t/ir i s/b i ts t r e a m/ handle/10665/68205/WHO_V_03.11_eng.pdf;jsessionid=2900A123BAB08299F0BBC7A87 BC1D51F?sequence=1
15. Word Health Organization – WHO. Polio laboratory manual. 2.ed . Geneva: WHO; 2004. [acesso 2018 Mai 29]. Disponível em: http://apps. who.int/iris/bitstream/handle/10665/68762/ WHO_IVB_04.10.pdf?sequence
16. Machado CM. Reimmunization after bone marrow transplantation--current recommendations and perspectives. Braz J Med Biol Res. 2004;37(1):151-8. http://dx.doi.org/10.1590/ S0100-879X2004000100021
17. Reed L, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27(3):493-7.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.
19. Fleiss JL. The measurement of interrater agreement. In: Fleiss JL, Statistical Methods for Rates and Proportions. New York: John Wiley;1981.p.212-36.
20. Siegel S, Castellan N. Nonparametric statistics for the behavioral sciences. 2.ed. New York: McGraw-Hill;1988.
21. Sistema de Informação de agravos de Notificação – SINAM. Paralisia flácida aguda/Poliomielite. [acesso 2018 Jun 5]. Disponível em: http://portalsinan. saude.gov.br/paralisia-flacida-aguda-poliomielite
22. Barbosa V, Stewien KE, Rosenburg CP. Estado vacinal, tipo de habitação e nível cultural da mãe e sua relação com o estado imunitário à poliomielite, em uma amostra de escolares do município de São Paulo, Brasil. Rev Saúde Pública. 1977;11:330-7.
23. Paul JR, Trask JD. The neutralization test in poliomyelitis. Comparative results with four strains of the virus. J Exp Med. 1935; 61(4):447–64. https://doi.org/10.1084/jem.61.4.447
24. Howitt BF. Poliomyelitis: in vitro neutralization tests, using normal adult and convalescent human serums. Cal West Med. 1935;43(6):407-11.
25. Herremans MM, Reimerink JH, Ras A, Van Der Avoort HG, Kimman TG, Van Loon AM et al. Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test. Clin Diagn Lab Immunol. 1997;4(6):659–64.
26. Hashido M, Horie H, Abe S, Doi Y, Hashizume S, Agboatwalla M et al Evaluation of an enzyme- linked immunosorbent assay based on binding inhibition for type-specific quantification of poliovirus neutralization-relevant antibodies. Microbiol Immunol. 1999;43(1):73–7. https://doi.org/10.1111/j.1348-0421.1999.tb02375.x
27. Ivanov AP, Dragunsky EM. ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines. Expert Rev Vaccines. 2005;4(2):167- 72. https:/doi.org/10.1586/14760584.4.2.167
28. Schepp RM, Berbers GAM, Ferreira JA, Reimerinka JH, Van der Klis FR. A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus. J Virol Methods. 2017;241:15–23. https://doi.org/10.1016/j. jviromet.2016.12.006
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2019 Revista do Instituto Adolfo Lutz